Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test guides new drug to stop breast Cancer's late return

NCT ID NCT06923527

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times

Summary

This study tests a drug called elacestrant in 50 adults with a type of breast cancer (ER+/HER2-) who have a high risk of the cancer coming back years later. Participants must have cancer DNA in their blood but no signs of spread on scans. The goal is to see if the drug can clear that DNA and improve survival without the cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+ BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Montefiore Einstein Comprehensive Cancer Center

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sidney Kimmel Comprehensive Cancer Center at John Hopkins

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Texas MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UPMC Hillman Cancer Center

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Email: •••••@•••••

    Contact

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.